menu
    • menu
    [{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Pegaspargase

    Menu

    Pegaspargase

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Erytech Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Erytech Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peg L asparaginase

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL

                            Details : Results from the NOPHO-sponsored Phase 2 clinical trial demonstrated that eryaspase in combination with chemotherapy, administered every two weeks, provides a sustained asparaginase enzyme activity level, and is generally well tolerated with few hypersen...

                            Brand Name : Eryaspase

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 20, 2021

                            Lead Product(s) : Peg L asparaginase

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Erytech Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Erytech Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peg L asparaginase

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ERYTECH's to Present Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia at the ASH 2020 Annu...

                            Details : Oral presentation to discuss findings from the Nordic Society of Paediatric Haematology and Oncology (NOPHO)-sponsored Phase 2 trial that confirm the potential of eryaspase as a treatment option for ALL.

                            Brand Name : Eryaspase

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 05, 2020

                            Lead Product(s) : Peg L asparaginase

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Erytech Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Erytech Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peg L asparaginase

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ERYTECH Provides Update on Phase 2 Investigator Sponsored Trial of Eryaspase in Second-Line Acute Lymphoblasti...

                            Details : Primary finding of the NOR-GRASPALL-2016 trial suggest that eryaspase achieved the target level and duration of asparaginase activity in these patients.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 09, 2020

                            Lead Product(s) : Peg L asparaginase

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Erytech Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Erytech Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peg L asparaginase,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ERYTECH Announces Poster Presentations at ASCO 2020 Annual Meeting

                            Details : TRYbeCA-1 is a randomized, controlled Phase 3 clinical trial evaluating eryaspase in second-line metastatic pancreatic cancer. The primary endpoint of TRYbeCA1 is overall survival (OS). The trial is designed to identify a OS hazard ratio (HR) of 0.72 wit...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 01, 2020

                            Lead Product(s) : Peg L asparaginase,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Erytech Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Erytech Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peg L asparaginase,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer

                            Details : ERYTECH’s lead product candidate, eryaspase, is being evaluated in a Phase 3 trial (TRYbeCA-1) in second-line metastatic pancreatic cancer in 11 countries in Europe and the United States.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 28, 2020

                            Lead Product(s) : Peg L asparaginase,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Erytech Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Erytech Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peg L asparaginase,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ERYTECH Provides Update on the TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer

                            Details : More than 75% of the planned ~500 patients enrolled in the trial evaluating eryaspase. Eryaspase is made of L-asparaginase placed inside donor-derived red blood cells.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 20, 2020

                            Lead Product(s) : Peg L asparaginase,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth